Active Biotech AB (BTPC)'s Partner Ipsen (IPN.PA) Initiates a Proof-of-Concept Study With Tasquinimod in Additional Cancer Indications
10/19/2012 8:48:43 AM
Lund, Sweden, October 19, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today
announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press release
here) will initiate a new phase II, proof-of-concept clinical trial with
tasquinimod in a so-called umbrella study evaluating the compound in four
different tumor types.